The role of IFN alpha in chronic myeloid leukaemia patients who have achieved a deep molecular response (DMR) is still unknown. The study reported by Irani et al., which shows the prospective biological effects of the drug in combination with a second-generation tyrosine kinase inhibitor, pave the way for further clinical studies aimed at increasing the rate of DMR for a possible successful discontinuation. Commentary on: Irani et al. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha. Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.18984.
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission? / Breccia, Massimo; Saglio, Giuseppe. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 202:6(2023), pp. 1087-1088. [10.1111/bjh.19013]
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
Breccia, Massimo;
2023
Abstract
The role of IFN alpha in chronic myeloid leukaemia patients who have achieved a deep molecular response (DMR) is still unknown. The study reported by Irani et al., which shows the prospective biological effects of the drug in combination with a second-generation tyrosine kinase inhibitor, pave the way for further clinical studies aimed at increasing the rate of DMR for a possible successful discontinuation. Commentary on: Irani et al. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha. Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.18984.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
